The Great Debate: Should Surgery be the "Standard of Care" for Stage IIIA NSCLC with Mediastinal Nodes?
It's over, and I won (did you doubt me?).
It's over, and I won (did you doubt me?).
Chemotherapy after surgery has become increasingly well established as beneficial for many patients who have undergone surgery for early stage NSCLC, at least for stage II and IIIA resected disease (stage IB has had more mixed results and remains quite debatable). The chemo regimens that have been most clearly shown to confer improved survival are cisplatin-based and can have very challenging toxicity in anybody, especially after a major lung surgery.
For many patients with early stage, resected NSCLC, chemotherapy after surgery may be a strong consideration to minimize the chance of the cancer returning, in which cases, it is often not possible to cure it. Several clinical trials over the past few years have shown benefits from chemo combinations, but which ones would be the leading considerations now?
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock